Skip to main content

Rocket Pharmaceuticals, Inc.

RCKT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001281895

In the last 90 days, Rocket Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 7 sales; 180 institutions reported holding it in 13F filings for Q2 2026, worth $340.9M in total; Maverick Capital is the only superinvestor holding it.

Q3 2021 vs. Q2 2021

How the institutions holding Rocket Pharmaceuticals, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of RCKT: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders150147−3
Shares61.9M62.0M+57.1K (+0.1%)
Value$2.74B$1.85B−$889.9M (−32.5%)

New holders (13)

Institutions that held Rocket Pharmaceuticals, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to RCKT in Q3 2021
InstitutionSharesValue% of portfolio
Novo Holdings A/S534,085$16.0M0.83%
International Biotechnology Trust PLC63,000$1.88M0.46%
Duality Advisers, LP40,763$1.22M0.09%
Cinctive Capital Management LP18,000$538.0K0.03%
Dynamic Technology Lab Private Ltd17,170$513.0K0.06%
Rockefeller Capital Management L.P.13,202$394.0K0.00%
Campbell & CO Investment Adviser LLC11,100$332.0K0.11%
Ovata Capital Management Ltd7,500$224.0K0.09%
Point72 Hong Kong Ltd6,630$198.0K0.02%
Banque Cantonale Vaudoise3,000$90.0K0.00%
Dark Forest Capital Management LP668$20.0K0.01%
Meridian Wealth Partners, LLC39$1.00K0.00%
Jefferies Group LLC1$300.00%

Sold out (16)

Institutions that held Rocket Pharmaceuticals, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.